Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 results; offers guidance

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 Revenue for the quarter at $69.55 million versus the consensus estimate of $67.72 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $310-320 million, versus the consensus of $316.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Freedom Broker Starts American States Water (AWR) at Hold
• UBS Downgrades Mondi PLC (MNDI:LN) (MONDY) to Neutral